Skip to main content
Premium Trial:

Request an Annual Quote

Thomas Schweins, Brad Crutchfield

Thomas Schweins has been appointed as head of the life science business area for Qiagen, CEO Peer Schatz noted in an earnings call this week. Schweins has been with Qiagen since 2004 and has been an integral part of the company's executive committee during this period, Schatz said. He also previously served as head of marketing and strategy at Qiagen, where he was involved in managing the company's global life science business. He also previously worked for Boston Consulting Group, Hoechst, and Aventis.

Schweins is taking over for Brad Crutchfield, who stepped down from the role for personal reasons, Schatz said.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.